Skip to main content
Fig. 2 | BMC Neuroscience

Fig. 2

From: Neuroprotective dobutamine treatment upregulates superoxide dismutase 3, anti-oxidant and survival genes and attenuates genes mediating inflammation

Fig. 2

Expression levels of genes determined by qPCR. To validate the findings of the micoarray the expression levels of a gene downregulated by dobutamine treatment, expression of a Sod3, b Ifit2, c ccl4 and d pgm5 were measured by qPCR. Levels are normalized Gapdh. Data are shown as mean ± SEM, with n = 14 (OGD); n = 9 (LPS + OGD); n = 9 (LPS + Dobutamine + OGD); n = 10 (Control); n = 7 (LPS); n = 8 (Dobutamine + LPS); n = 6 (Dobutamine + OGD); n = 8 (Dobutamine). Differences were assessed as described in the Methods section for independent samples between all experimental groups. The following differences were obtained: *p < 0.05, **p < 0.001, ***p < 0.0001. a Sod3: p < 0.0001 OGD dobutamine versus control, versus LPS, versus LPS dobutamine and versus OGD; LPS dobutamine OGD versus control, versus LPS, versus LPS dobutamine and versus OGD. p < 0.001 OGD dobutamine versus dobutamine; LPS dobutamine OGD versus dobutamine. p < 0.05 OGD versus LPS OGD. b Ifit1: p < 0.0001 LPS versus OGD; LPS OGD versus control, versus LPS dobutamine, dobutamine, OGD, OGD dobutamine, LPS dobutamine OGD; p < 0.001 LPS versus, control, versus dobutamine, versus OGD dobutamine, versus LPS dobutamine OGD. c Ccl4: p < 0.0001 LPS versus all other experimental groups; p < 0.05 LPS dobutamine versus control. d Pgm5: No significant differences have been obtained (p < 0.18)

Back to article page